Cardiology Pharma Marketing
& Medical Communications India.

Cardiology — India's most competitive branded generic battleground

The cardiology pharma market in India is shaped by branded-generic competition at unprecedented density. The 5 leading statin molecules have 200+ branded-generic competitors. The top 10 antihypertensive molecules have 400+ branded-generic competitors. Antiplatelet, anticoagulant, and combination therapy categories show similar density. Efficacy differentiation is essentially impossible at the molecule level. Brand wins are determined by communications quality, MR relationship depth, and HCP engagement sophistication.

The non-efficacy differentiation axes

In a category where all brands deliver equivalent efficacy, the differentiation axes shift to: tolerability (adverse event profile, drug-drug interaction risk, hepatic/renal safety in comorbid patients), patient adherence support (pill burden, dosing frequency, real-world adherence data), combination therapy positioning (FDC efficacy and safety vs free-dose combination), and HCP relationship depth (MR call frequency, KOL engagement, and the quality of the scientific narrative).

ICG's cardiology brand communications are built on these four axes. Every detailing piece, every CLM module, every patient education leaflet is scored on whether it advances one or more of these dimensions. Communications that don't move a differentiation axis are removed from the brand mix.

UCPMP and the branded-generic constraint

UCPMP 2024 specifically prohibits unsubstantiated comparative claims between branded generics. A brand cannot claim "better efficacy than [Brand X]" without head-to-head trial data — which almost never exists in branded-generic categories. UCPMP also prohibits claims of "superior tolerability" without comparative pharmacovigilance evidence. The discipline pushes brand communications toward the non-comparative — what this brand does, on what evidence, for which patient profile — and away from the cross-brand comparative.

HCP engagement — the cardiology field force model

Cardiology field force operations are among India's most sophisticated. Top-quartile cardiology brands maintain MR-to-HCP ratios that allow monthly visits to high-prescribing cardiologists, quarterly visits to mid-tier prescribers, and semi-annual visits to GP/internist prescribers. ICG's Pharos RxFlow + RouteIQ + Signal stack is deployed across cardiology engagements to make this field force model data-driven — every MR visit informed by prior engagement data, every territory routed for productive engagement time, and every conversation analysed for coaching insight.

Outcome targets

(1) Brand prescriber share lift — measurable via Rx audit integrated with Pharos Pulse. (2) MR call productivity — 25–40% lift in productive HCP engagement time within 6 months. (3) KOL advisory board quality — measurable via paired KOL surveys. (4) Patient adherence programme impact — measurable on real-world adherence cohorts.